View more in
Science

Zanubrutinib May Be Superior to Ibrutinib in Relapsed/Refractory CLL/SLL

onclive.com
 2021-06-11

Zanubrutinib induced superior response and progression-free survival rates, as well as lower rates of atrial fibrillation/flutter than ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Zanubrutinib (Brukinsa) induced superior response and progression-free survival (PFS) rates, as well as lower rates of atrial fibrillation/flutter than ibrutinib (Imbruvica) in patients...

www.onclive.com

Comments / 0

Comments / 0